Does Cigna cover Wegovy, Zepbound, Ozempic and Mounjaro?
The short answer
Cigna covers Wegovy injection, Zepbound, Saxenda and Foundayo with prior authorization if your plan includes the benefit. Its standard coverage policies first ask for at least 3 months of behavioral modification and dietary restriction, and a baseline BMI of 30, or 27 with a weight-related condition. Ozempic and Mounjaro require a documented type 2 diabetes diagnosis. Your benefit plan can still exclude a drug.
Key takeaways
- Ask Cigna or your benefits team first whether your plan covers weight-loss medicines. Your plan document overrides the policy.
- For adult weight loss, you need prior authorization and at least 3 months of behavioral modification and dietary restriction.
- The baseline BMI must be 30 or more, or 27 or more with a weight-related condition.
- Ozempic and Mounjaro need a documented type 2 diabetes diagnosis. Policy IP0701 doesn't cover them for weight loss alone.
- Wegovy renewal needs at least 5 percent loss of baseline body weight, so record your starting weight.
What the published policies say
Cigna Healthcare: Foundayo commercial covered with pa
Cigna's standard drug coverage policy requires prior authorization for Foundayo. It is approved for weight loss in adults with obesity, or with overweight plus a weight-related condition. The policy notes that an individual benefit plan can still exclude the drug.
- Age 18 or older, with at least 3 months of behavioral modification and dietary restriction first
- Baseline BMI of 30 or more, or 27 or more with a weight-related condition
- Used together with behavioral modification and a reduced-calorie diet
- Initial approval 8 months, then 1 year
Prior Authorization is required for benefit coverage of Foundayo. ... Foundayo is considered medically necessary when the following are met:
Weight Loss – Glucagon-Like Peptide-1 Agonists – Foundayo (Coverage Policy Number IP0206)
Cigna Healthcare: Mounjaro commercial covered with pa
On Cigna employer-plan drug lists, Mounjaro requires prior authorization and is approved for one year when the patient has a documented diagnosis of type 2 diabetes. The policy lists weight loss in a person without type 2 diabetes as a use that is not covered.
- Documented diagnosis of type 2 diabetes
- Not approved for weight loss without type 2 diabetes
- Approval lasts 1 year
Prior Authorization is required for benefit coverage of the GLP-1 agonists and GLP-1/GIP agonist targeted in this policy. ... Diagnosis of Type 2 diabetes mellitus [Documentation Required]
Cigna Healthcare: Ozempic commercial covered with pa
On Cigna employer-plan drug lists, Ozempic requires prior authorization and is approved for one year when the patient has a documented diagnosis of type 2 diabetes. The policy lists weight loss in a person without type 2 diabetes as a use that is not covered.
- Documented diagnosis of type 2 diabetes
- Not approved for weight loss without type 2 diabetes
- Approval lasts 1 year
Prior Authorization is required for benefit coverage of the GLP-1 agonists and GLP-1/GIP agonist targeted in this policy. ... Diagnosis of Type 2 diabetes mellitus [Documentation Required]
Cigna Healthcare: Saxenda commercial covered with pa
Cigna's standard drug coverage policy requires prior authorization for liraglutide for weight loss (Saxenda and its generic). It is approved for adults and for adolescents with obesity. On employer plans, brand Saxenda additionally requires that the patient has tried generic liraglutide and cannot take it.
- Adults: age 18 or older, with at least 3 months of behavioral modification and dietary restriction first
- Baseline BMI of 30 or more, or 27 or more with a weight-related condition
- Brand Saxenda on employer plans: generic liraglutide must have been tried first
- Initial approval 4 months, then 1 year
Prior Authorization is required for benefit coverage of liraglutide (Saxenda, generic). ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
Weight Loss – Glucagon-Like Peptide-1 Agonists – Liraglutide (Coverage Policy Number IP0813)
Cigna Healthcare: Wegovy commercial covered with pa
Cigna's standard drug coverage policy requires prior authorization for Wegovy injection (including Wegovy HD). It is approved for adult and adolescent weight loss, for heart-risk reduction in adults with established cardiovascular disease, and for MASH. The policy notes that an individual benefit plan can still exclude the drug, and the plan document overrides the policy.
- Adult weight loss: age 18 or older, with at least 3 months of behavioral modification and dietary restriction first
- Baseline BMI of 30 or more, or 27 or more with a weight-related condition
- Used together with behavioral modification and a reduced-calorie diet
- Initial approval 8 months; renewal for 1 year requires at least 5 percent loss of baseline body weight
- Cardiovascular risk reduction: baseline BMI of 27 or more plus prior heart attack, stroke, or symptomatic peripheral arterial disease
Prior Authorization is required for benefit coverage of Wegovy injection (Wegovy and Wegovy HD). ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
Weight Loss – Glucagon-Like Peptide-1 Agonists – Wegovy Injection (Coverage Policy Number IP0814)
Cigna Healthcare: Zepbound commercial covered with pa
Cigna's standard drug coverage policy requires prior authorization for Zepbound. It is approved for adult weight loss and for moderate to severe obstructive sleep apnea in adults with obesity. The policy notes that an individual benefit plan can still exclude the drug, and the plan document overrides the policy.
- Weight loss: age 18 or older, with at least 3 months of behavioral modification and dietary restriction first
- Baseline BMI of 30 or more, or 27 or more with a weight-related condition
- Initial approval 8 months; renewal for 1 year requires at least 5 percent loss of baseline body weight
- Sleep apnea: baseline BMI of 30 or more and a sleep study showing at least 15 events per hour
Prior Authorization is required for benefit coverage of Zepbound. ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
Weight Loss – Glucagon-Like Peptide-1 Agonists – Zepbound (Coverage Policy Number IP0816)
Policies differ between plans from the same insurer and change during the year. Your own plan documents decide.
Cigna Healthcare writes a separate coverage policy for each weight-loss GLP-1, plus one policy for the diabetes GLP-1s on its employer-plan drug lists. This page covers six of them.
One sentence in these documents matters more than any criterion: an individual benefit plan can still exclude the drug, and the plan document overrides the policy. A Cigna policy tells you what a request must show if the benefit exists. It doesn’t tell you that your employer bought the benefit.
The weight-loss policies: Wegovy, Zepbound, Saxenda, Foundayo
All four need prior authorization (the plan’s approval before it pays), and the adult criteria follow one pattern:
- Age 18 or older.
- A trial of behavioral modification and dietary restriction for at least 3 months before the drug.
- A baseline BMI (your body mass index before treatment) of 30 or more, or 27 or more with a weight-related condition.
- Use together with behavioral modification and a reduced-calorie diet.
Three months of documented lifestyle effort is a shorter lead-in than some insurers ask for, and the BMI thresholds are the familiar 30 and 27. Most of the work is in the documentation: chart notes showing when the lifestyle trial started, and a recorded baseline weight.
Wegovy injection (policy IP0814, including Wegovy HD). Approved for adult and adolescent weight loss, for heart-risk reduction in adults with established cardiovascular disease, and for MASH, a liver condition. The cardiovascular route asks for a baseline BMI of 27 or more plus a prior heart attack, stroke or symptomatic peripheral arterial disease. First approval is 8 months, and a 1-year renewal requires at least 5 percent loss of baseline body weight.
Zepbound (IP0816). Approved for adult weight loss and for moderate to severe obstructive sleep apnea in adults with obesity. The sleep apnea route asks for a baseline BMI of 30 or more and a sleep study showing at least 15 events per hour. Approval lengths match Wegovy’s.
Saxenda and generic liraglutide (IP0813). Approved for adults and for adolescents with obesity. On employer plans, brand Saxenda is approved only after generic liraglutide has been tried and can’t be taken. First approval is 4 months, then 1 year.
Foundayo (IP0206). Approved for weight loss in adults with obesity, or with overweight plus a weight-related condition. First approval is 8 months, then 1 year.
The diabetes policy: Ozempic and Mounjaro
Policy IP0701 covers Cigna’s employer-plan drug lists (Standard, Performance, Value, Advantage, Legacy and Total Savings). Ozempic and Mounjaro need prior authorization and are approved for 1 year with a documented diagnosis of type 2 diabetes. The policy lists weight loss in a person without type 2 diabetes as a use that isn’t covered, so a request for either drug for weight alone doesn’t fit it.
Next steps with a Cigna plan
Start by confirming the benefit. Ask Cigna, or your employer’s benefits team, whether your plan covers weight-loss medicines and which drug list it uses. If the benefit exists, your prescriber submits the prior authorization with the 3-month lifestyle record and baseline BMI. Our prior authorization checklist covers the documents.
If you get a denial, the reason decides what you do next. A missing document can be supplied. A plan exclusion is a benefit question, and the denial appeal guide explains the difference. The appeal letter tool builds a letter from your details.
With coverage in place, the manufacturer savings cards can lower a covered fill to as little as $25. Without it, Lilly’s separate offer for commercial plans that don’t cover the Zepbound pen is $499 a month, and self-pay Zepbound starts at $299.
Frequently asked questions
Does Cigna cover Zepbound for weight loss?
Cigna's coverage policy IP0816 requires prior authorization for Zepbound. It can be approved for adults with a baseline BMI of 30 or more, or 27 or more with a weight-related condition, after at least 3 months of behavioral modification and dietary restriction. The policy notes that an individual benefit plan can still exclude the drug.
Does Cigna cover Ozempic for weight loss?
Not under the policy we hold. Cigna's employer-plan policy IP0701 approves Ozempic for one year when there's a documented diagnosis of type 2 diabetes. It lists weight loss in a person without type 2 diabetes as a use that isn't covered. The same rule applies to Mounjaro.
Does Cigna make you try generic liraglutide before Saxenda?
On employer plans, yes. Cigna's liraglutide policy IP0813 says brand Saxenda also requires that the patient has tried generic liraglutide and can't take it. The other adult criteria match Cigna's other weight-loss policies: age 18 or older, a 3-month lifestyle trial and the BMI thresholds. The first approval is 4 months, then 1 year.
How long is a Cigna prior authorization for Wegovy good for?
Under policy IP0814 the first approval for Wegovy injection for weight loss is 8 months. Renewal is for 1 year and requires at least 5 percent loss of baseline body weight. Zepbound and Foundayo follow the same 8-month first approval, and Saxenda starts with 4 months.
Sources (7)
- 1.Cigna Healthcare: Weight Loss – Glucagon-Like Peptide-1 Agonists – Foundayo (Coverage Policy Number IP0206)
“Prior Authorization is required for benefit coverage of Foundayo. ... Foundayo is considered medically necessary when the following are met:”
- 2.Cigna Healthcare: Diabetes – Glucagon-Like Peptide-1 Agonists for Employer Plans: Standard/Performance, Value/Advantage, Legacy, Total Savings Prescription Drug Lists (Coverage Policy Number IP0701)
“Prior Authorization is required for benefit coverage of the GLP-1 agonists and GLP-1/GIP agonist targeted in this policy. ... Diagnosis of Type 2 diabetes mellitus [Documentation Required]”
- 3.Cigna Healthcare: Weight Loss – Glucagon-Like Peptide-1 Agonists – Liraglutide (Coverage Policy Number IP0813)
“Prior Authorization is required for benefit coverage of liraglutide (Saxenda, generic). ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND”
- 4.Cigna Healthcare: Weight Loss – Glucagon-Like Peptide-1 Agonists – Wegovy Injection (Coverage Policy Number IP0814)
“Prior Authorization is required for benefit coverage of Wegovy injection (Wegovy and Wegovy HD). ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND”
- 5.Cigna Healthcare: Weight Loss – Glucagon-Like Peptide-1 Agonists – Zepbound (Coverage Policy Number IP0816)
“Prior Authorization is required for benefit coverage of Zepbound. ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND”
- 6.
- 7.
Related pages
- What insurance covers Wegovy, Zepbound and other GLP-1 medicines?
- Wegovy and Zepbound prior authorization: a criteria checklist
- How to appeal a Wegovy or Zepbound insurance denial
- Zepbound savings card, plus the Wegovy, Ozempic and Mounjaro cards
- Appeal letter generator
- Does CVS Caremark cover Zepbound and Foundayo?
